Relay Therapeutics Stock Today
| RLAY Stock | USD 3.28 0.06 1.80% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Relay Therapeutics is trading at 3.28 as of the 20th of March 2025; that is 1.8 percent decrease since the beginning of the trading day. The stock's open price was 3.34. Relay Therapeutics has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 169.52 M outstanding shares of which 15.79 M shares are at this time shorted by private and institutional investors with about 10.69 trading days to cover. More on Relay Therapeutics
Moving together with Relay Stock
Moving against Relay Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Relay Stock Highlights
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Relay Therapeutics (RLAY) is traded on NASDAQ Exchange in USA. It is located in 399 Binney Street, Cambridge, MA, United States, 02142 and employs 261 people. Relay Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 594.17 M. Relay Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 169.52 M outstanding shares of which 15.79 M shares are at this time shorted by private and institutional investors with about 10.69 trading days to cover.
Relay Therapeutics currently holds about 1.05 B in cash with (249.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Relay Therapeutics Probability Of Bankruptcy
Ownership AllocationRelay Therapeutics owns a total of 169.52 Million outstanding shares. The majority of Relay Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Relay Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Relay Therapeutics. Please pay attention to any change in the institutional holdings of Relay Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million eight hundred fourty-seven thousand seven hundred ninety invesors are currently shorting Relay Therapeutics expressing very little confidence in its future performance.
Check Relay Ownership Details
Relay Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Relay Therapeutics market risk premium is the additional return an investor will receive from holding Relay Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | 0.1965 | |||
| Treynor Ratio | 0.2387 |
Relay Stock Against Markets
Relay Therapeutics Corporate Management
| Deborah Palestrant | Vice Strategy | Profile | |
| MA MBA | Pres CEO | Profile | |
| Thomas Catinazzo | Chief Officer | Profile | |
| Andy Porter | Chief Officer | Profile | |
| Jim Watters | Chief Research | Profile |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.